Congratulations to the Eagle Genomics team for closing their £6.91M Series A investment round. The new investment will be used to further develop the capabilities of Eagle Genomics’ powerful AI-augmented, knowledge discovery platform and to drive further commercial expansion across Europe and the US.
Rob Genieser, Partner at ETF Partners, shared his support stating, “We are delighted to see Eagle Genomics go from strength to strength, and to be able to support this crucial next stage of growth. The timing could not be better, with the world’s focus on disease and accelerated innovation and ever more in-silico innovation. We wish the team all the best in expanding its reach and deepening its capabilities.”
Read more here: PRNewsWire